2 Under-the-Radar Biotech Stocks to Buy in 2023
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. And over the past few years, some companies that focus partly or entirely on gene editing have become more prominent as the possibilities the technology could help unlock become clearer.
However, they remain relatively anonymous, especially compared to the biggest players in the biotech industry. But that's no reason for investors to ignore them. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
CRISPR Therapeutics has severely underperformed the market in the past 12 months. Here are some of the reasons why. First, although its leading pipeline programs have made progress (more on that in a bit), it still has no approved product. And second, like most clinical-stage biotechs, it is currently unprofitable. Given the challenging economic conditions and marketwide troubles, it isn't surprising to see investors sell off stocks like CRISPR Therapeutics.
Source Fool.com
